The clinical model combining Ki-67 and primary tumour site showed poor performance in both the development (training 0.57 [0.40–0.74] and validation 0.56 [0.30–0.82]) and test sets (0.23 [0–0.46]). The gene discussed is MKI67; the disease is neoplasm.